STI Pharma, located in Newtown, PA, was founded in 2008 by a team of industry veterans.
Acquired 6 Products
Acquired 6 generic products (ANDAs) from a global generic pharmaceutical company. Launched Dexamethasone Elixir, Betamethasone Valerate Lotion, Sulfatrim Suspension and Escitalopram Tablets
Contracted with a 3rd party logistics provider (3PL) to provide warehousing, shipping and accounting services for STI’s products. During this time STIi initiated label and marketing capabilities.
Transition to Injectable Products
STI Began transitioning its focus to developing injectable products.
Developed 6 generic injectables products, transitioned the products to manufacturing sites. STI submitted and managed the injectable dossiers with the FDA to approval.
R&D Lab Built
Built R&D laboratories dedicated to formulation development and analytical services
Launched Cyclophosphamide (1st Oncology product).
FDA Approvals of Carmustine and Arsenic Trioxide
FDA Approval of Carmustine (1st injectable product). FDA Approval of Arsenic Trioxide (2nd injectable product).
Commercial Launch of Carmustine and FDA Approval of Thiotepa
Commercial launch of Carmustine and FDA approval of Thiotepa (3rd injectable product)
3 Product Launches and Expanded Pipeline
Launch of Thiotepa, Arsenic Trioxide and Succinylcholine (1st Commercial License). Expanded pipeline to include 12+ injectable products ranging from oncology to complex peptides
Commercial Launch of Isoproterenol Hydrochloride
Launch of Isoproterenol Hydrochloride Injection, USP 1 mg/5 mL